Song Yang, Cai Xiaoli, Ostermeyer Grayson, Yu Jierui, Du Dan, Lin Yuehe
School of Mechanical and Material Engineering, Washington State University, Pullman, Washington 99164, United States.
Immuno Diagnostics Division and Biomonitoring, Evergreen System Inc., Seattle, Washington 98105, United States.
ACS Sens. 2021 Jan 22;6(1):220-228. doi: 10.1021/acssensors.0c02148. Epub 2021 Jan 12.
Paper-based rapid diagnostic tests, such as immunochromatographic assays, namely lateral flow immunoassay (LFA), are valuable alternatives for biomarker detection compared to traditional laboratory-based tests, but these assays need further refinement to consolidate their biosensing capabilities. Nanozyme integration into LFA systems may provide a reliable means of improving the analytic sensitivity of LFA tests. Due to the involvement of multiple liquid-handling steps, the quantitative accuracy is compromised, hence hindering the use of untrained personnel point-of-care use. Self-assembling allochroic nanocatalyst (SAN) assemblies satisfy these LFA quality measures by optimizing analyte-antibody reporting performance and by intrinsically catalyzing chromogen activation, thereby reducing the number of liquid handling steps involved during sample analysis. In SANs, the hydrophobic chromogens serve as peroxidase substrates that self-assemble into nanoparticles at high loading fractions. These features demonstrate the potential for SAN-LFAs to be a valuable patient point-of-care (POC) test. Herein, we describe the SAN fabrication process and employ SAN-LFAs to detect cardiac troponin I-troponin C (cTnI-TnC) and myoglobin (Myo) levels present in plasma samples. Using SAN-LFAs, the limits of detection for cTnI-TnC and Myo were 0.012 ng/mL and 0.2 ng/mL respectively. We also demonstrate SAN compatibility with blood samples and stability under long-term storage conditions. The successful utlization of SANs in LFA-based biomarker detection may inspire these nanocatalysts to be integrated into similar immunochromatographic testing methods.
基于纸质的快速诊断测试，如免疫层析测定法，即侧向流动免疫测定法（LFA），与传统的基于实验室的测试相比，是生物标志物检测的有价值的替代方法，但这些测定法需要进一步改进以巩固其生物传感能力。将纳米酶整合到LFA系统中可能提供一种提高LFA测试分析灵敏度的可靠方法。由于涉及多个液体处理步骤，定量准确性受到影响，因此阻碍了未经培训的人员在现场护理点使用。自组装变色纳米催化剂（SAN）组件通过优化分析物-抗体报告性能和内在催化色原激活来满足这些LFA质量标准，从而减少样品分析过程中涉及的液体处理步骤数量。在SAN中，疏水性色原作为过氧化物酶底物，以高负载分数自组装成纳米颗粒。这些特性表明SAN-LFA有潜力成为一种有价值的患者现场护理（POC）测试。在此，我们描述了SAN的制备过程，并使用SAN-LFA检测血浆样品中存在的心肌肌钙蛋白I-肌钙蛋白C（cTnI-TnC）和肌红蛋白（Myo）水平。使用SAN-LFA，cTnI-TnC和Myo的检测限分别为0.012 ng/mL和0.2 ng/mL。我们还证明了SAN与血液样品的兼容性以及在长期储存条件下的稳定性。SAN在基于LFA的生物标志物检测中的成功应用可能会促使这些纳米催化剂被整合到类似的免疫层析测试方法中。
